Gene Therapy for Cardiac Arrhythmias

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Regenerative Medicine

Background:

• Cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, pose significant morbidity and mortality risks.
• Conventional treatments for cardiac arrhythmias have limitations, with some cases remaining refractory to therapy.
• Gene therapy presents a novel therapeutic avenue for managing cardiac arrhythmias.

Purpose of the Study:

• To explore gene therapy as an additional or alternative treatment for cardiac arrhythmias.
• To investigate gene therapy strategies for bradycardia, atrial fibrillation, and ventricular tachycardia.
• To assess the potential of gene and cell-based therapies in treating refractory arrhythmias.

Main Methods:

• Development of "biological pacemaker" strategies using viral vectors to modify ion channel function for bradycardia.
• Application of gene therapy to increase effective refractory period or restore conduction velocity for tachycardia.
• Utilizing gene and cell hybrid therapies, and stem cell-derived pacemaker cells.
• Testing therapeutic concepts in large animal models of cardiac arrhythmias.

Main Results:

• Gene therapy approaches demonstrated the potential to convert quiescent myocytes into spontaneously active cells for bradycardia.
• Strategies targeting refractory period and conduction velocity showed promise in eliminating or reducing tachyarrhythmias in animal models.
• Proof-of-concept established for gene therapy as an adjuvant or alternative for cardiac arrhythmias.

Conclusions:

• Gene therapy is a viable concept for treating cardiac arrhythmias, offering new hope for refractory cases.
• Current limitations include the need for improved long-term efficacy and safety data.
• Advancements in gene delivery methods are crucial for clinical translation of these therapies.